Humanized Anti-CD25 Antibody Treatment with Daclizumab in Multiple Sclerosis

By  

Neurodegenerative Diseases, Vol. 5, Iss. 1, 2007-12 ,pp. : 23-26

Karger

Access to resources Recommend Favorite

CIRCULATING SERUM LEVELS OF IL-1ra IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS ARE NORMAL DURING REMISSION PHASES BUT SIGNIFICANTLY INCREASED EITHER DURING EXACERBATIONS OR IN RESPONSE TO IFN-beta TREATMENT

By Nicoletti F.   Patti F.   Marco R.D.   Zaccone P.   Nicoletti A.   Meroni P.   Reggio A.  

Cytokine, Vol. 8, Iss. 5, 1996-04 ,pp. : 395-400

Academic Press

Access to resources Recommend Favorite

The genetic analysis of multiple sclerosis

By Sawcer S.   Goodfellow P.N.   Compston A.  

Trends in Genetics, Vol. 13, Iss. 6, 1997-06 ,pp. : 234-239

Elsevier

Access to resources Recommend Favorite

Therapeutic Antibodies in Multiple Sclerosis

By  

Neurodegenerative Diseases, Vol. 5, Iss. 1, 2007-12 ,pp. : 5-7

Karger

Access to resources Recommend Favorite

SHORT-TERM TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS WITH INTERFERON (IFN)-β1B TRANSIENTLY INCREASES THE BLOOD LEVELS OF INTERLEUKIN (IL)-6, IL-10 AND IFN-γ WITHOUT SIGNIFICANTLY MODIFYING THOSE OF IL-1β, IL-2, IL-4 AND TUMOUR NECROSIS FACTOR-α

By Nicoletti F.   Di Marco R.   Patti F.   Zaccone P.   L'Episcopo M.R.   Reggio E.   Xiang M.   Nicoletti A.   Reggio A.  

Cytokine, Vol. 12, Iss. 6, 2000-06 ,pp. : 682-687

Academic Press

Access to resources Recommend Favorite